investing

Merck Amgen

Analysts Ritholtz Wealth Management highlight Merck & Co., Inc. (MRK) and Amgen (AMGN) as biotech stocks show significant breakout potential

Merck's recent Phase 3 trial success in combination therapy has significantly boosted its stock, indicating a positive shift in investor sentiment towards its pipeline. This development, along with Amgen's strong performance, highlights a broader resurgence in the biotech sector, which could attract more investor interest.
Brinker International

Analysts Baird initiated coverage of Brinker International (EAT) with an outperform rating and a $325 target price, indicating 32% upside

Brinker International, the owner of Chili's, has received an 'outperform' rating from Baird, which sees significant growth potential for the stock, projecting a 32% upside from its current price due to the ongoing turnaround of the casual dining chain.